Baclofen in the Treatment of Spasticity

Baclofen† (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ 1971-10, Vol.4 (5778), p.15-17
Hauptverfasser:	Hudgson, P., Weightman, D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aminobutyrates - adverse effects Aminobutyrates - therapeutic use Clinical Trials as Topic Electromyography Experimentation Female Humans Injections, Intravenous Intravenous injections Lower extremity Male Middle Aged Multiple sclerosis Multiple Sclerosis - complications Muscle Spasticity - drug therapy Nausea - chemically induced Papers and Originals Paralysis - etiology Placebos Pretreatment Side effects Spinal cord diseases Spinal Cord Diseases - complications Standard error Statistical results Vertigo - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Baclofen† (Lioresal), a derivative of gamma-aminobutyric acid, was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Preliminary studies suggested that it may be more effective than other spasmolytic agents currently available, and a double-blind controlled trial in a group of 23 patients against placebo has shown it to be significantly more effective.
ISSN:	0007-1447 0959-8138 1468-5833
DOI:	10.1136/bmj.4.5778.15